Le Lézard14 小时
Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application ...
Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment.Troriluzole demonstrated a 50-70% slowing of SCA disease progression on the ...
Biohaven Ltd.: Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New ...
Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. Troriluzole demonstrated a 50-70% slowing of SCA disease progression ...